Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The administration of ex vivo expanded natural killer (NK) cells as potential antitumor effector cells appears to be suitable for effector cell-based immunotherapies in high-risk cancer patients. However, good manufacturing practice (GMP)-compliant manufacturing of clinical-grade NK cells at sufficiently high numbers represents a great challenge. Therefore, previous expansion protocols for those effector cells were improved and optimized by using newly developed culture medium, interleukin (IL)-21, and autologous feeder cells (FCs). Separation of primary human NK cells (CD56 + CD3 − ) was carried out with the CliniMACS Prodigy ® in a single process, starting with approximately 1.2 × 10 9 leukocytes collected by small-scale lymphapheresis or from buffy coats. Enriched NK cells were adjusted to starting cell concentrations within approximately 1 × 10 6 effector cells/mL and cultured in comparative expansion experiments for 14 days with IL-2 (1,000 IU/mL) in different GMP-compliant media (X-VIVO ™ 10, CellGro ® , TexMACS ™ , and NK MACS ® ). After medium optimization, beneficial effects for functionality and phenotype were investigated at the beginning of cell expansion with irradiated (25 Gy) autologous FCs at a ratio of 20:1 (feeder: NK) in the presence or absence of IL-21 (100 ng/mL). Additionally, expanded NK cells were gene modified to express chimeric antigen receptors (CARs) against CD123, a common marker for acute myeloid leukemia (AML). Cytotoxicity, degranulation, and cytokine release of transduced NK cells were determined against KG1a cells in flow cytometric analysis and fluorescent imaging. The Prodigy manufacturing process revealed high target cell viabilities (median 95.4%), adequate NK cell recovery (median 60.4%), and purity of 95.4% in regard to CD56 + CD3 - target cells. The process in its early phase of development led to a median T-cell depletion of log 3.5 after CD3 depletion and log 3.6 after the whole process, including CD3 depletion and CD56 enrichment steps. Manually performed experiments to test different culture media demonstrated significantly higher NK cell expansion rates and an approximately equal distribution of CD56 dim CD16 pos and CD56 bright CD16 dim&neg NK subsets on day 14 with cells cultivated in NK MACS ® media. Moreover, effector cell expansion in manually performed experiments with NK MACS ® containing IL-2 and irradiated autologous FCs and IL-21, both added at the initiation of the culture, induced an 85-fold NK cell expansion. Compared to freshly isolated NK cells, expanded NK cells expressed significantly higher levels of NKp30, NKp44, NKG2D, TRAIL, FasL, CD69, and CD137, and showed comparable cell viabilities and killing/degranulation activities against tumor and leukemic cell lines in vitro . NK cells used for CAR transduction showed the highest anti-CD123 CAR expression on day 3 after gene modification. These anti-CD123 CAR-engineered NK cells demonstrated improved cytotoxicity against the CD123 pos AML cell line KG1a and primary AML blasts. In addition, CAR NK cells showed higher degranulation and enhanced secretion of tumor necrosis factor alpha, interferon gamma, and granzyme A and B. In fluorescence imaging, specific interactions that initiated apoptotic processes in the AML target cells were detected between CAR NK cells and KG1a. After the fully automated NK cell separation process on Prodigy, a new NK cell expansion protocol was generated that resulted in high numbers of NK cells with potent antitumor activity, which could be modified efficiently by novel third-generation, alpha-retroviral SIN vector constructs. Next steps are the integration of the manual expansion procedure in the fully integrated platform for a standardized GMP-compliant overall process in this closed system that also may include gene modification of NK cells to optimize target-specific antitumor activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
Perforin-mediated target-cell death and immune homeostasis
Voskoboinik, I., Smyth, M. J., & Trapani, J. A. (2006) · Nature reviews. Immunology · doi:10.1038/nri1983 · Cited by 592 · cited 1×
“5 In addition, death receptor ligands such as FasL (fas ligand) or TRAIL (tumor necrosis factor [TNF]-related apoptosis-inducing ligand) expressed by the NK cells are able to induce caspase-dependent apoptosis of target cells.”
IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
McMichael, E. L., Jaime-Ramirez, A. C., Guenterberg, K. D., Luedke, E., Atwal, L. S., Campbell, A. R., Hu, Z., Tatum, A. S., Kondadasula, S. V., Mo, X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0004 · Cited by 70 · cited 2×
“18,19 First re-sults in combining FCs, IL-21, and IL-2 showed a sustained proliferation of human NK cells.”
Cited by
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
“(http://creativecommons.org/licenses/by-nc-nd/4.0/) Keywords: Chimeric antigen receptor NK cells Immunotherapy Cancer n receptor; CAR-T, CAR-engiersus-host disease; CRS, cytoatural cytotoxicity receptors; KIRs, killer cell Ig-like recepcity; IgG, immunoglobulin G; ing lymphocyte; TCR-T, TCRngle-chain variable fragment…”
BackgroundInfluentialNatural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
Lupo, K. B., & Matosevic, S. (2019) · Cancers · doi:10.3390/cancers11060769 · Cited by 196
“IL-18 was shown to stimulate IFN-γ production by NK cells and provide co-stimulatory activation [84], while IL-21 [85] was able to enhance maturation of NK cells without promoting proliferation.”
BackgroundEfficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector
Colamartino, A. B. L., Lemieux, W., Bifsha, P., Nicoletti, S., Chakravarti, N., Sanz, J., Roméro, H., Selleri, S., Béland, K., Guiot, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02873 · Cited by 187
“High 26 transduction rates were also observed after NK-cell expansion on K562-mbIL15-41BBL 27 feeder cells(9) or feeder-free NK MACS medium(15) (Figure 1D).”
BackgroundChimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00998-9 · Cited by 171
DIGIUSTO, D. L., MELSOP, K., SRIVASTAVA, R., & TRAN, C.-A. T. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.07.008 · Cited by 22
Metadata
- Authors
- Klöß, S., Oberschmidt, O., Morgan, M., Dahlke, J., Arseniev, L., Huppert, V., Granzin, M., Gardlowski, T., Matthies, N., Soltenborn, S., Schambach, A., & Koehl, U.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2017-10
- Volume
- 28
- Issue
- 10
- Pages
- 897-913
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2749736858
- Cited by
- 136
- References
- 3
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.